Markets:

Overview

News

Currencies

International

Treasuries

Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

22.74 +0.66 (+2.99%)

Streaming Delayed Price Updated: 1:08 PM EDT, Jul 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Syndax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 07, 2022

Gainers

Via Benzinga

Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92 ↗

June 30, 2022

Syndax Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 80 to 92.

Via Investor's Business Daily

12 Health Care Stocks Moving In Friday's After-Market Session ↗

April 29, 2022

Gainers Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million.

Via Benzinga

Do Penny Stocks Ever Make Money? Here Are 7 Success Stories ↗

April 10, 2022

Penny stocks can make money. Success stories include Advanced Micro Devices, a former penny stock that earned a $3.2 billion net income in 2021. Here are six others.

Via InvestorPlace

Syndax Pharmaceuticals's Return On Capital Employed Overview ↗

March 07, 2022

According to Benzinga Pro, during Q4, Syndax Pharmaceuticals (NASDAQ:SNDX) earned $96.20 million, a 566.1% increase from the preceding quarter. Syndax Pharmaceuticals also posted...

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

Earnings Scheduled For May 9, 2022 ↗

May 09, 2022

Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2022 ↗

April 11, 2022

Upgrades

Via Benzinga

Recap: Syndax Pharmaceuticals Q4 Earnings ↗

March 01, 2022

Syndax Pharmaceuticals (NASDAQ:SNDX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement....

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2022 ↗

February 15, 2022

Upgrades For Blue Bird Corp (NASDAQ:BLBD), Roth Capital upgraded the previous rating of Neutral to Buy. Blue Bird earned $0.07 in the first quarter, compared to $0.00 in the year-...

Via Benzinga

The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures ↗

February 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda ↗

December 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 16, 2021

Gainers Calliditas Therapeutics (NASDAQ:CALT) stock rose 41.09% to $26.3 during Thursday's pre-market session. The market value of their outstanding shares is at $688....

Via Benzinga

The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street ↗

December 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug...

Via Benzinga

Syndax Pharma Posts Additional Data On Clinical Activity, Responses From Early-Stage Leukemia Trial ↗

December 14, 2021

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) revealed updated data from the Phase 1 dose-escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with...

Via Benzinga

Earnings Preview For Syndax Pharmaceuticals ↗

November 12, 2021

Syndax Pharmaceuticals (NASDAQ:SNDX) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement....

Via Benzinga

Earnings Scheduled For November 15, 2021 ↗

November 15, 2021

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third quarter. • Tyson Foods (NYSE:TSN) is estimated to...

Via Benzinga

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More ↗

November 14, 2021

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 04, 2021

Gainers Evaxion Biotech (NASDAQ:EVAX) stock moved upwards by 157.5% to $16.74 during Thursday's regular session. Evaxion Biotech's stock is trading at a volume of...

Via Benzinga

81 Biggest Movers From Yesterday ↗

November 05, 2021

Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares jumped 95.1% to close at $12.68 on Thursday after dropping over 10% on Wednesday. TDH Holdings, Inc. (NASDAQ: PETZ) jumped 79.8...

Via Benzinga

55 Stocks Moving In Thursday's Mid-Day Session ↗

November 04, 2021

Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares climbed 179% to $18.17 after dropping over 10% on Wednesday. NerdWallet, Inc. (NASDAQ: NRDS) jumped 60% to $28.86 after the...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 05, 2021

Gainers Ocugen (NASDAQ:OCGN) shares moved upwards by 11.11% to $7.5 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.4...

Via Benzinga

The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive ↗

September 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...

Via Benzinga

Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate ↗

September 27, 2021

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 27, 2021

Gainers Syndax Pharmaceuticals (NASDAQ:SNDX) shares moved upwards by 8.94% to $20.48 during Monday's pre-market session. The company's market cap stands at $995.9...

Via Benzinga

Syndax Pharmaceuticals's Return On Capital Employed Insights ↗

September 14, 2021

According to data from Benzinga Pro, during Q2, Syndax Pharmaceuticals's (NASDAQ:SNDX) reported sales totaled $379.00 thousand. Despite a 17.78% increase in earnings, the...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

September 09, 2021

Gainers IVERIC bio (NASDAQ:ISEE) shares ...

Via Benzinga

44 Stocks Moving In Monday's Mid-Day Session ↗

June 28, 2021

Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software...

Via Benzinga

Earnings Scheduled For August 9, 2021 ↗

August 09, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.